Coverage
-
April 07, 2026
A class of investors has reached a deal with Biogen Inc. to avoid a trial and resolve a suit over statements executives made as they launched an Alzheimer's drug, according to a Tuesday filing in Massachusetts federal court.
6 other articles on this case.
View all »